Dosimetric impact of bone marrow sparing for robustly optimized IMPT for locally advanced cervical cancer
CONCLUSION: Achieving 1 GyRBE BMS for IMPT is feasible for LACC patients with limited dosimetric impact on other OARs. While further bone marrow dose reduction is possible for some patients, it may increase OAR doses substantially for others. Hence, we recommend a personalized approach when introducing BMS into clinical IMPT treatment planning to carefully assess individual patient benefits and risks.PMID:38471634 | DOI:10.1016/j.radonc.2024.110222
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: S C Kuipers J Godart A Corbeau S Breedveld J W M Mens S M de Boer R A Nout M S Hoogeman Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Cervical Cancer | Colorectal Cancer | Men | Proton Therapy | Radiology | Women